预约演示
更新于：2025-11-27
Brimonidine Tartrate
酒石酸溴莫尼定
更新于：2025-11-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS号70359-46-5 |
关联
151
项与 酒石酸溴莫尼定 相关的临床试验NCT04007276
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%
Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
开始日期2026-11-10 |
申办/合作机构- |
NCT07209410
Impact of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.
开始日期2025-11-01 |
NCT07082764
A Phase 2a Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy
Taxane -induced peripheral neuropthy (TIPN) and nail toxicites are frequent side effects of taxane therapy in breast cancer patients.. TIPN involves the hands and the feet ,its symptoms comprise numbness,tingling,altered touch sensation, impaired vibration, parasthesia and dysesthesias induced by touch, warm or cool temperatures.
This study investigate the preventive effect of TAR-0520 gel on TIPN and on nail toxicity.
Breast cancer patients under taxanes therapy will apply TAR-0520 Gel to one hand and the homolateral foot including fingers and toes. Other hand and foot will be untreated and will serve as control.
Patients will be followed during the 12 cycles of taxane therapy. Evaluations of TIPN will include clinical assessments by the oncologist, examination by a neurologist, patient questionnaires administered by a nurse and objective neurophysiological measures conducted by trained personnel. Evaluation of taxane nail toxicity will include a clinical grading by a nurse and a patient questionnaire.
This study investigate the preventive effect of TAR-0520 gel on TIPN and on nail toxicity.
Breast cancer patients under taxanes therapy will apply TAR-0520 Gel to one hand and the homolateral foot including fingers and toes. Other hand and foot will be untreated and will serve as control.
Patients will be followed during the 12 cycles of taxane therapy. Evaluations of TIPN will include clinical assessments by the oncologist, examination by a neurologist, patient questionnaires administered by a nurse and objective neurophysiological measures conducted by trained personnel. Evaluation of taxane nail toxicity will include a clinical grading by a nurse and a patient questionnaire.
开始日期2025-09-01 |
申办/合作机构 |
100 项与 酒石酸溴莫尼定 相关的临床结果
登录后查看更多信息
100 项与 酒石酸溴莫尼定 相关的转化医学
登录后查看更多信息
100 项与 酒石酸溴莫尼定 相关的专利（医药）
登录后查看更多信息
2,593
项与 酒石酸溴莫尼定 相关的文献（医药）2025-10-01·EXPERIMENTAL EYE RESEARCH
Cross-species and cross-platform analysis reveals the application value of guinea pig retina in myopia research at single-cell resolution
Article
作者: Yang, Yifang ; Chen, Minyu ; Liang, Guimei ; Liu, Jiahui ; Liu, Qingyang ; Li, Shuyan
This study delineates the single-cell transcriptomic landscape of pigmented guinea pig retinas-an emerging model for myopia research-through integrated single-cell and bulk RNA sequencing, cross-species comparative analysis, and functional validation using form-deprivation myopia models with intravitreal brimonidine intervention. Our results identified six major retinal cell types (rod cells, cone cells, bipolar cells, Müller glial cells, astrocytes, and retinal pigment epithelial cells) subdivided into 16 distinct subclusters, revealing multilineage pseudo time trajectories and specialized intercellular signaling networks: rod cells via NEGR/CADM, cone cells via MPZ, bipolar cells via SEMA6/PTPRM, and astrocytes via ESAM. Cross-species alignment demonstrated closer phylogenetic alignment with human retinal architecture than murine counterparts in pseudo time trajectories and cellular crosstalk. In therapeutic models, brimonidine treatment decelerated axial elongation while inducing selective reductions in cone cells, bipolar cells, and pigment epithelium, paralleled by concordant gene expression shifts. By establishing the first single cell atlas of guinea pig retina and validating its similarities to human ocular biology, this work not only consolidates guinea pigs as a valuable model for myopia research but also infers cellular and molecular dynamics underlying antimyopic interventions, offering a cross-species framework for retinal disease mechanism exploration and therapeutic development.
2025-09-01·Actas Dermo-Sifiliograficas
Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis
Review
作者: Gao, X ; Xiang, W
Topical interventions for rosacea are often used to relieve local symptoms. However, currently, there are few articles to systematically analyze the efficacy profile of topical drugs for rosacea. This study aimed to investigate the efficacy profile of widely used topical drugs. To acquire appropriate information from related literature, we looked into 4 databases. Efficacy was appraised with the Investigator Global Assessment, Clinician's Erythema Assessment, Patient's Self-Assessment and Subject Self-Assessment of Rosacea Facial Redness scales. Treatment-emergent adverse events and dermal tolerability were also recorded. According to 21 randomized controlled trials included, a total of 6 topical drugs including minocycline, ivermectin, azelaic acid, metronidazole, brimonidine and oxymetazoline were reported. These drugs are well-tolerated and safe. Ivermectin is more effective than azelaic acid and metronidazole. Azelaic acid has a better efficacy profile than metronidazole according to included studies. Minocycline turned out to be effective improving the symptoms of rosacea. Brimonidine and oxymetazoline both have significant effects on reducing facial redness.
2025-09-01·Advances in Skin & Wound Care
A Split-face Randomized Comparative Study of Efficacy of Pulsed Dye Laser, Topical Brimonidine Tartrate, and Their Combination for Treatment of Post-acne Erythema
Article
作者: Al-Jarem, Yehia Farouk ; El Banaa, Alshaimaa Mohamed ; Omar, Shaimaa I ; Essawy, Marwa
OBJECTIVE::
To investigate and compare the effectiveness and safety of pulsed dye laser (PDL), topical brimonidine tartrate, and their combined use in post-acne erythema (PAE) treatment.
METHODS::
In this randomized clinical comparative trial, 60 patients who had PAE on both sides of the face were equally divided into 2 groups. According to a split-face design, the PAE lesions in each participant of group A were randomly treated with PDL followed by brimonidine tartrate on one side and PDL alone on the other one. Alternatively, PAE lesions on each face side in group B were treated with a single-treatment modality, either brimonidine or PDL. The efficiency of treatments was assessed by the Global Assessment of Improvement scores, by the clinical assessment of PAE lesion count, and patient satisfaction, as well as objective morphometric analysis of the patient photographs.
RESULTS::
Significant improvement was noticed subjectively and objectively after treatment with PDL alone, brimonidine alone, and PDL+brimonidine compared with baseline. In group A, PDL+brimonidine achieved superior improvement with regard to global assessment of improvement, percentage of lesion count reduced, erythema index, and patient satisfaction.
CONCLUSIONS::
Pulsed dye laser and topical brimonidine separately proved to be effective and safe in the treatment of PAE. Their combination can have an additively positive therapeutic outcome.
156
项与 酒石酸溴莫尼定 相关的新闻（医药）2025-11-23
·青学药
该药医保基础信息
注射用罗普司亭N01（外文名：Romiplostim N01 for Injection），商品名瑞立升®，是齐鲁制药有限公司研发的第二代长效血小板生成素受体激动剂（TPO-RA）。2024年4月经国家药品监督管理局批准上市，适用于适用于对其他治疗（例如皮质类固醇、免疫球蛋白）反应不佳的成人（ ≥ 18 周岁）慢性免疫性血小板减少症（ITP）患者，注意的是仅用于因血小板减少和临床条件导致出血风险增加的 ITP 患者，不应以将血小板计数恢复至正常水平作为治疗目的。该药采用重组DNA技术制成的Fc肽融合蛋白，属于生物药3.4类。该药品推荐起始剂量为1μg/kg每周一次皮下注射，最大剂量不超过10μg/kg。Ⅲ期临床试验显示其24周持续血小板反应率达61.8%，2025年1月1日起被纳入国家医保目录，作为唯一国产长效TPO-RA类药物，具有每周给药、无肝毒性等优势，2024年5月6日正式发往全国市场，并获《促血小板生成药物临床应用管理中国专家共识（2023）》推荐，该药物10项研究成果入选2025年美国血液学会年会（ASH）
注意事项：
1. 停止治疗后血小板减少复发和出血
基于罗普司亭 N01 的临床试验结果，以及同类产品罗普司亭的用药经验，停用罗普司亭 N01 后，血小板减少症可能复发：成人患者可能会发生比罗普司亭 N01 治疗前更严重的血小板减少症。如果在使用抗凝血剂或抗血小板药物的情况下停止使用罗普司亭 N01，则出血风险增加。应密切监测患者的血小板计数降低，并在停止使用罗普司亭 N01 后立即采取医疗措施，以避免发生出血。停用罗普司亭 N01 后，应根据当前治疗指南，至少连续 2 周监测血常规（包括血小板计数），并考虑采取针对血小板减少症恶化的其他治疗手段。如果终止罗普司亭 N01 治疗，建议遵照当前治疗指南重新开始 ITP 治疗，其他的医疗措施可能包括停止抗凝和/或抗血小板治疗、逆转抗凝或血小板支持。
2. 骨髓网硬蛋白增加
在接受罗普司亭 N01 治疗前，在一些 ITP 患者中观察到骨髓中的网硬蛋白，并且在接受罗普司亭 N01 治疗的一些患者中有增加趋势。骨髓网硬蛋白被认为是 TPO 受体刺激导致骨髓中巨核细胞数量增加的结果，进而可能释放细胞因子。在罗普司亭 N01 的临床研究中，未发现网硬蛋白与不良临床后遗症、慢性特发性骨髓纤维化或继发性骨髓纤维化之间的相关性。停用罗普司亭 N01 后可能改善。网硬蛋白增加可能表现为外周血细胞的形态学变化，并可通过骨髓活检检测到。因此，建议在罗普司亭 N01 治疗前和治疗期间使用外周血涂片和全血细胞计数（CBC）来检查细胞形态学异常。如果在患者中观察到疗效丧失和外周血涂片异常，应停止使用罗普司亭 N01，进行体格检查，并考虑对网硬蛋白进行适当染色的骨髓活检。如果可行，应当与之前的骨髓活检结果进行比较。如果疗效持续，但观察到患者外周血涂片异常，医生应遵循适当的临床判断，包括考虑骨髓活检，并应重新评估罗普司亭 N01 的风险获益和替代 ITP 治疗方案。
3. 血栓性/血栓栓塞性并发症
高于正常范围的血小板计数存在血栓性/血栓栓塞性并发症的理论风险。伴有已知的血栓栓塞危险因素的患者应慎用罗普司亭 N01。这些危险因素包括但不限于遗传危险因素（例如因子 V Leiden 突变）或获得性危险因素（例如 ATIII 缺乏症、抗磷脂综合征）、高龄、长期卧床、恶性肿瘤、避孕药和激素替代疗法、手术/创伤、肥胖及吸烟。基于同类产品罗普司亭的用药经验，已接受罗普司亭治疗的慢性肝病患者发生血栓栓塞事件（TEE）的报道，包括门静脉血栓形成。在这些人群中应慎用罗普司亭 N01，应遵循剂量调整指南
4. 骨髓增生异常综合征（MDS）有进展为急性髓系白血病（AML）的风险
TPO 受体刺激因子是导致血小板生成祖细胞扩增、分化和血小板生成的造血生长因子。TPO 受体主要表达在髓系细胞表面，在实体瘤上没有经确认的 TPO 受体表达。理论上 TPO 受体激动剂具有促使 MDS 发生进展的风险。在临床试验中接受罗普司亭 N01 治疗的 238 例受试者中共 5 例（2.1%）发生 5 例次与造血系统恶性肿瘤或 MDS 相关的不良反应，均为骨髓纤维化。
文献推荐：
往期回顾：
雷珠单抗治疗知多少？一文读懂雷珠单抗！
国内第6款PD-L1：索卡佐利单抗注射液
偏头痛创新药：硫酸瑞美吉泮口崩片
遗传性血管性水肿（HAE）急性期治疗药物醋酸艾替班特注射液
恩曲他滨丙酚替诺福韦片(Ⅱ)
中枢性α2肾上腺素受体激动剂：盐酸替扎尼定片
降低开角型青光眼及高眼压症患者的眼内压药：酒石酸溴莫尼定滴眼液
临床3期上市批准
2025-11-19
本文来源于：青白视角
01 强生全视
强生 10 月 14 日报道称，J&J Vision 2025 年第三季度的全球收入总计 14.00 亿美元，较2024年第三季度的 13.00 亿美元增长7.7%。美国收入同比增长 4.2%，美国境外增长10.2%。
视觉外科（眼力健）收入 ：全球总计为 3.83 亿美元，比 2024 年第三季度的 3.33 亿美元增长 14.9%。2025 年第三季度美国的视觉外科收入为 1.16 亿美元，比 2024 年第三季度的 1.08 亿美元增长了 7%；而美国以外的收入为 2.66 亿美元，比 2024 年第三季度的 2.25 亿美元增长了 18.7%。视觉外科的增长得益于近期产品创新（Tecnis PureSee、Tecnis Odyssey 和 Tecnis Eyhance）的强劲势头、旺盛的需求以及强大的商业执行力。
隐形眼镜/其他（视力健）收入：为 10 亿美元，较2024年第三季度的9.68亿美元增长5.2%。该季度美国地区的隐形眼镜业务营收为4.56亿美元，较4.41亿美元增长3.5%；美国以外地区的营收为5.62亿美元，较2024年第三季度的5.27亿美元增长6.6%。
强生公司 2025 年第三季度的总收入为 240 亿美元，比 2024 年第三季度的 225 亿美元增长 6.8%。
02 博士伦
博士伦 10 月 29 日公布，其 2025 年第三季度营收总计 13 亿美元，比 2024 年第三季度的 12 亿美元增长 7%。
2.1 视力保健业务
2025 年第三季度收入为 7.36 亿美元，比 2024 年第三季度的 6.84 亿美元增长了 8%。推动增长的因素包括消费者业务中非处方干眼症产品组合和眼部维生素的销售，以及隐形眼镜业务中 SiHy Daily 镜片和 Biotrue ONEday 镜片的增长。
2.2 外科手术业务
2025年第三季度收入为 2.15 亿美元，比 2024 年第三季度的 2.06 亿美元增长了 4%，主要原因是设备销售和植入耗材销售增加，而这又受到高端人工晶状体增长的推动。
2.3 眼科药物业务
2025 年第三季度收入为 3.3 亿美元，比 2024 年第三季度的 3.06 亿美元增长 8%。增长主要归功于 Miebo 销售额的增长和国际药品业务的增长。
2.4 报告期内业务亮点
在所有业务板块均实现了全面营收增长，其中眼科药物和视力保健业务表现尤为突出。
在干眼症领域，MIEBO® 实现了强劲增长，并扩大了领导地位。
随着enVista®和 LUX 平台的增长，高端人工晶状体市场重获发展势头。
先进的研发管线包括：下一代 LUMIFY®的III 期研究已达到所有主要和次要终点，并已启动生物活性隐形眼镜、下一代 lifitegrast、眼表疼痛和青光眼临床研究的患者招募。
2.5 全年销售指引
博士伦公司维持了其 2025 年的收入预期，预计全年收入将在 50.5 亿美元至 51.5 亿美元之间，按固定汇率计算比 2024 年增长 5% 至 7%。
03 依视路陆逊梯卡
依视路陆逊梯卡 10 月 16 日宣布，2025 年第三季度的综合收入达到 68.67 亿欧元（约79亿美元），同比增长了 11.7%。整体呈现 “季度业绩创历史最佳、全年增长稳健、创新与并购驱动未来” 的特点。从区域来看，北美、欧洲中东及非洲（EMEA）市场表现突出，亚太地区实现稳健增长，拉丁美洲增速有所放缓；从业务来看，专业解决方案与直接面向消费者两大业务板块均实现双位数增长，智能眼镜成为核心增长驱动力。
3.1 按业务划分
专业解决方案业务：第三季度收入为 32.23 亿欧元，与 2024 年同期相比 增长 了 11.9%。北美和 EMEA 地区贡献双位数增长，，亚太、拉美中个位数增长。Ray-Ban 品牌受 AI 智能眼镜带动表现突出，近视管理解决方案（如 Stellest 镜片）、Varilux Physio Extensee、Nikon Z等创新镜片产品成为增长关键。
直接面向消费者业务：第三季度收入为 36.44 亿欧元，与 2024 年同期相比增长了 11.6%；实体门店与电商渠道协同发力，可比门店销售额增长超 7%，AI 智能眼镜（Ray-Ban Meta Gen 2、Oakley Meta HSTN 等新品）推动电商实现双位数增长，Supreme 整合共同支撑高增速。
3.2 按区域划分
四大区域中，北美和 EMEA 以双位数增长成为核心驱动力，亚太保持稳健，拉美增速较前两季度有所放缓。
3.3 重点介绍亚太地区（尤其中国）业务
亚太地区营收达 8.22 亿欧元，较 2024 年第三季度增长 10.5%。这一增长得益于大中华区业务的加速发展，Supreme 的整合也进一步推动了营收增长。
在专业解决方案板块，大中华区的近视管理解决方案表现强劲，同比增长约 20%，这一增长尤其得益于尼康（Nikon）和柯达（Kodak）的 DOT 镜片。随着 7 月 Stellest 2.0 镜片及 Stellest 镜框的推出，该集团的旗舰品牌在近视管理领域的高品质地位持续巩固。镜框业务方面，奥克利（Oakley）势头迅猛，吸引了众多新客户；奢侈授权品牌则实现了双位数增长。东南亚和韩国市场增长势头强劲，均实现双位数增长。
直接面向消费者板块，凭借稳健的有机增长实现发展，同店销售额达低个位数增长，Supreme 的整合也为该板块营收带来了额外贡献。澳大利亚的 OPSM 品牌业绩小幅增长，这得益于其订阅计划 —— 该计划在现有客户和新客户中均获得认可。在部分试点门店，集团部署了用于干眼症治疗的 Espansione 仪器，并收到了积极反馈。该地区的太阳镜 hut（Sunglass Hut）营收持平，这一稳定表现得益于人工智能眼镜（AI-glasses）受欢迎程度的上升，而新人工智能功能的推出也为其提供了助力。3.4 战略动态：创新 + 并购，构建 “视力健康生态”
集团通过 “产品创新” 和 “战略并购” 双路径，强化在可穿戴设备、近视管理、眼科医疗领域的布局，核心动作包括：3.4.1 产品创新：AI 眼镜引领可穿戴革命，近视管理突破市场AI 眼镜（可穿戴设备）
2025 年 9 月发布新一代产品，包括 Ray-Ban Meta Gen 2、Oakley Meta HSTN、Meta Ray-Ban Display，持续领跑智能眼镜品类，成为 Q3 营收 “关键增量”（拉动 Ray-Ban、Oakley 品牌及电商增长）；Stellest 镜片（近视管理）
获美国 FDA “de novo” 完全批准，2025 年 10 月起在美国市场上市，填补美国青少年近视管理市场空白；同时在大中华区推出 Stellest 2.0 及配套镜框，巩固近视管理领导地位。3.4.2 战略并购：强化医疗科技（Med-Tech）能力
完成 Optegra 眼科诊所收购，2025 年 10 月起并入集团报表，完善眼科医疗服务端布局；
宣布收购 RetinAI（AI 眼科诊断技术公司），将 AI 驱动的预防与治疗结合，构建 “从产品到服务” 的视力健康生态。
视网膜药物表现
04 罗氏
罗氏于 10 月 23 日报告称，2025 年第三季度 Vabysmo 的销售额为 9.96 亿瑞士法郎（约为 12.5 亿美元），比 2024 年第三季度的 10.22 亿瑞士法郎下降了 2.5%。
4.1 Vabysmo
Vabysmo 是首个针对眼科疾病开发的VEGF-A/ANG-2双特异性抗体，主要适应症包括湿性年龄相关黄斑变性和糖尿病黄斑水肿、视网膜静脉阻塞引起的黄斑水肿等。与单纯anti-VEGF疗法相比，其用于治疗多种视网膜疾病可以实现减少眼部注射给药频率。Vabysmo 目前已在美国、英国、日本、欧盟等全球80多个国家和地区获批上市。2023年12月，中国NMPA正式批准法瑞西单抗（商品名罗视佳）用于治疗糖尿病黄斑水肿（DME）。
本季度，Vabysmo 在美国的销售额为 6.89 亿瑞士法郎，而 2024 年第三季度为 7.75 亿瑞士法郎；美国以外地区的销售额为 3.07 亿瑞士法郎，而 2024 年第三季度为 2.47 亿瑞士法郎。罗氏表示，Vabysmo 在早期上市国家持续扩大市场份额，并有望在全球范围内扩张。该公司指出，约60%的美国新患者此前未接受过任何治疗。
4.2 其他眼科药物
Lucentis ：2025 年第三季度，在美国的销售额为 900 万瑞士法郎（1130 万美元），而 2024 年第三季度为 3200 万瑞士法郎。在美国的基本、主要专利已经过期。专利到期药的 Lucentis曾为罗氏眼科业务的主力，为了应对仿制药和阿柏西普的竞争，罗氏开发了双抗Vabysmo，后者超出预期地完成了接力。
补充：
诺华于 10 月 28 日报告称，其 2025 年第三季度在美国以外地区 (OUS) 销售的 Lucentis 收入总计 1.48 亿美元，比 2024 年第三季度的 2.45 亿美元下降了 40%。该公司将业绩下滑归因于竞争加剧导致的销售额下降。
Luxturna：2025 年第三季度 Luxturna 的收入为 300 万瑞士法郎（380 万美元），而 2024 年第三季度为 500 万瑞士法郎。通过眼内注射带有正常RPE65基因的腺相关病毒（AVV），在视网膜色素上皮细胞中表达该基因，从而恢复患者视力。用于治疗特定的遗传性眼疾，是美国首款上市的基因疗法，针对遗传性罕见病并靶向特定基因突变的“直接给药型”疗法。单眼治疗费用为42.5万美元，双眼治疗费用为85万美元，但如果疗效不显著，患者无需支付全款。2017年12月，FDA批准Spark治疗公司（2019年被罗氏收购）研发的基因疗法。
Susvimo：2025 年第三季度 Susvimo 的收入为 200 万瑞士法郎（250 万美元），与 2024 年第三季度的 200 万瑞士法郎持平。
注册进展：用于含Lucentis的端口递送系统PDS，现称为Susvimo （2021Q4/FDA）。Susvimo是FDA批准的第1个将nAMD患者眼球注射次数减少到每年2次的新疗法。2022年10月，基因泰克和罗氏因测试显示“一些植入物不符合基因泰克的标准”而将其撤出市场。2024 年在美国重新上市，并于 2025 年 5 月新增糖尿病视网膜病变的适应证标签。Susvimo 可以帮助糖尿病视网膜病变患者维持视力，并防止病情发展为失明，每九个月只需进行一次治疗。Susvimo正在接受欧洲药品管理局（EMA）的审查，一旦获批，它将成为首个用于治疗nAMD的持续给药疗法，该疾病在欧盟影响着170万患者。来自 LADDER 研究的最新七年数据显示，输液港平台 Contivue 联合 Susvimo 治疗可带来良好的视觉效果，并能长期维持稳定的视网膜解剖结构，每年最多可补充两次，提供可靠的长期视力改善效果，并已在美国获准用于治疗新生血管性年龄相关性黄斑变性 (nAMD)、糖尿病性黄斑水肿 (DME) 和糖尿病性视网膜病变 (DR)。
05 再生元
再生元 10 月 28 日报告称，其 2025 年第三季度美国 Eylea（阿柏西普 2 毫克）和 Eylea HD（阿柏西普 8 毫克）的收入为 11 亿美元，比 2024 年第三季度的 15.4 亿美元下降了 28%，其中 Eylea HD 的收入为 4.31 亿美元，比 2024 年第三季度增长了 10%。
Eylea HD 于 2023 年 8 月获得美国批准，再生元于 2023 年第三季度开始记录销售额。该公司表示，Eylea HD 净销售额增长主要得益于销量增加，而销量增加又是由需求增长推动的，但部分被净售价下降所抵消。
Eylea 净销售额受到以下因素的负面影响：持续的竞争压力导致销量下降；由于患者经济承受能力有限，导致市场份额被复合贝伐珠单抗蚕食；以及患者持续向Eylea HD过渡；此外，净售价下降也是影响Eylea净销售额的因素之一。
该公司 2025 年第三季度与拜耳在美国以外地区销售 Eylea 两款产品相关的合作收入为 3.448 亿美元，比 2024 年第三季度的 3.908 亿美元下降了 11.7%。
2025 年第三季度 Eylea HD 和 Eylea 2 mg 的全球总销售额为 20 亿美元，比 2024 年第三季度的 24.7 亿美元下降了 20%。
06 STAAR
STAAR 11 月 5 日公布，2025 年第三季度净销售额为 9470 万美元，同比增 6.9%、环比大幅增长，其中包含 2024 年 12 月中国经销商 2750 万美元延期付款发货的剩余 2590 万美元（本季度全额收回并确认收入）。不含中国地区净销售额 3890 万美元，同比增 7.7%。不过，本季度中国经销商因精益库存管理减少新订单，且近九个月中国经销商累计减库存 8000 万 - 8500 万美元（含上述延期发货），未新增采购，导致该期间销售额低于上年同期。该笔延期发货相关 ICL 手术于 2025 年全年持续开展。
1.1 ICL销售额情况
美洲地区 ICL 销售额为 721 万美元，比 2024 年第三季度增长 6%。
亚太地区 ICL 销售额为 7716 万美元，销售额增长了 6%，其中中国市场增长了 6%，收入为 5583 万美元，而第二季度下降了 92%，第一季度下降了 102%，2024Q4下降了81%。
欧洲、中东和非洲地区表现强劲，销售额为 1036 万美元，增长了 8%。
1.2 重大商业变动
关于爱尔康拟15亿美元收购STAAR案，可回顾点击：STAAR-Alcon并购事件
07 豪雅
豪雅 10 月 31 日公布，公司截至 2025 年 10 月 31 日总收入（即 2025 财年第二季度）为2345亿日元，比 2024 年同期的约 2151 亿日元增长9%。
2.1 生活护理业务
生活护理业务收入为1469 亿日元，同比增长8%。眼镜镜片的双位数增长成为板块增长核心驱动力。
其中眼镜镜片同比增长为10%，渐进镜片及镀膜等增值产品在欧洲市场表现良好。德国和加拿大的补强型并购（Bolt-on M&A）也为销售额增长做出了贡献。目前已纳入法国保险覆盖范围的 MiYOSMART 产品需求激增。公司将继续针对各个市场推行定制化策略。
其中隐形眼镜同比增长 5%，自有品牌产品和订阅服务提升了客户留存率，高附加值产品销售持续扩大，包括硅水凝胶（SiHy）等高端材料产品及多焦点镜片，同时通过积极开店拓展新客户，2025 财年第二季度新增 3 家门店，上半年累计新增 7 家。
医疗相关产品：其医疗部门（人工晶状体、内窥镜和人造骨）在 2025 年第三季度（即 2025 财年第二季度）的收入为 337 亿日元（2.268 亿美元），比 2024 年同期的 318 亿日元增长了 5.9%。
人工晶状体增长了3%。从区域销售情况来看，该公司表示，在日本，医院和诊所的IOL销售情况依然稳健，部分原因是新产品的推出。在欧洲，核心系统更换造成的销售中断已经缓解，公司看到需求正在逐步恢复。豪雅表示，受中国集采政策（NVBP）的影响，其在中国的销售持续受到影响。豪雅正在调整其在中国的战略，包括将目标客户群转向医院。总体而言，该公司正致力于扩大高端人工晶状体产品（如三焦点人工晶状体）的销售。
2.2 信息技术业务
非医疗领域略。08 艾伯维
艾伯维10月31日报告，其 2025 年第三季度眼科护理净收入为 5.09 亿美元，比 2024 年第三季度的 5.25 亿美元下降了 3%。
Ozurdex（眼底类固醇药物）营收为 1.17 亿美元，较 2024 年第三季度的 1.19 亿美元下降 1.6%。
Lumigan/Ganfort（青光眼降压药物）在2025年第三季度的收入为9700美元，同比去年第三季度下降15.9%。主要受到美国市场下降26.1%的影响，全球市场负增长6%。
Alphagan/Combigan（青光眼降压药物）在2025年第三季度的收入为4700万美元，同比去年第三季度下降24.7%。主要受到美国市场下降67.4%的影响。
“其他眼部护理”（包括许多非处方药和处方药，如 Vuity，以及 Xen 凝胶支架等设备）创造了 2.48 亿美元的收入，比 2024 年第三季度的 2.07 亿美元增长了 8.8%。
艾伯维2025年第三季度总体净收入为157.76亿美元，比2024年第三季度增长了9.1%。
09 Glaukos
Glaukos 于 10 月 29 日公布，其 2025 年第三季度净销售额创历史新高，总计 1.335 亿美元，同比增长 38%。
4.1 青光眼业务
2025 年第三季度青光眼净销售额创历史新高，达到 1.102 亿美元，同比增长 45%。美国青光眼产品2025 年第三季度净销售额创历史新高，达到 8080 万美元，同比增长57%。
4.2 角膜健康业务
角膜健康业务销售额为 2330 万美元，比 2024 年第三季度的 2060 万美元增长了 13%。
4.3 视网膜疾病管线
Glaukos 正在开发多种微创生物可降解的缓释药物输送平台，旨在用于治疗各种视网膜疾病，包括AMD、RVO、DME等。
4.4 业界最全的眼科手术和药物研发管线
Glaukos 正在“推进业界最全的眼科手术和药物研发管线”，在青光眼、角膜健康和视网膜疾病领域建立卓越的下一代手术和药物疗法组合（更新至2025年11月）：
4.5 全年销售指引
Glaukos 将 2025 年净销售额预期从之前的 4.8 亿美元至 4.86 亿美元上调至 4.9 亿美元至 4.95 亿美元。10 Lumibird
Lumibird 于 10 月 27 日报告称，2025 年前三季度录得营收 1.551 亿欧元，同比增长 9.6%。其医疗部门 2025 年第三季度的收入为 2310 万欧元（2710 万美元），比 2024 年第三季度的 2340 万欧元下降了 1.6%。此次增长暂停源于交付延迟至 2025 年第四季度，不影响医疗部门的增长势头。前 9 个月营收 7860 万欧元，同比增长 5.9%，其中 77% 来自治疗业务，23% 来自诊断业务。
医疗部门由 Quantel Medical、Ellex 和 Optotek Medical 组成。
该公司表示，医疗部门继续受益于在澳大利亚和日本的直接业务活动。该公司指出，加强美国销售团队的举措已初见成效，但美洲地区的增长受到南美业务暂时放缓的影响。Lumibird 表示，预计 2025 年第四季度业务活动就像每年一样将保持高水平。
11 爱尔康
爱尔康于 11 月 11 日公布，其 2025 年第三季度净销售额总计 26 亿美元，比 2024 年第三季度的 24 亿美元增长 6%。
1.1 外科手术业务
2025 年第三季度，外科手术业务净销售额（含植入物、耗材及设备 / 其他业务）为 14 亿美元，比 13 亿美元增长了 6%。
植入物：净销售额为 4.32 亿美元，增长 2% 是由 PanOptix Pro IOL 的推出推动的，但被持续的竞争压力所抵消。
耗材：净销售额为7.45亿美元，增长6%，反映出市场状况改善和价格上涨。
设备/其他：净销售额为2.43亿美元，增长 13%，这主要得益于近期推出的设备，这一增长主要得益于近期推出的新设备，包括Unity VCS。
1.2 视力保健业务
2025 年第三季度，视力保健业务净销售额（含隐形眼镜和眼健康产品）为12 亿美元，比 2024 年第三季度的 11 亿美元增长了 7%。
隐形眼镜：净销售额为7.07亿美元，增长6%。增长主要得益于产品创新和价格上涨，但部分被传统产品销售额的下滑所抵消。
眼部健康：净销售额为4.62亿美元，增长7%。增长主要得益于干眼症和青光眼治疗产品的销售，包括Systane、Tryptyr和Rocklatan，但部分被隐形眼镜护理业务的下滑所抵消。上年同期数据包含部分在中国销售的眼药水，这些眼药水已于2024年底剥离并授权给欧康维视。
1.3 全年销售指引
爱尔康维持了其全年营收预期，为 103 亿美元至 104 亿美元。
12 Immunocore
Immunocore 于 11 月 6 日报告称，截至 2025 年 9 月 30 日止的三个月和九个月，KIMMTRAK 的净产品销售额分别为 1.037 亿美元和 2.955 亿美元，与 2024 年同期相比分别增长了 29% 和 31%。
从区域来看，Kimmtrak 的净收入包括美国 6730 万美元，同比增长 18%，平均治疗持续时间延长至 14 个月。欧洲 3350 万美元和其他国际地区的 290 万美元，受需求增加和在更多市场推出产品的推动，欧洲和国际地区合计季度销售额同比增长 58%。该公司表示，收入增长主要归功于美国和欧洲销量的增长以及全球扩张。
KIMMTRAK 是一种新型双特异性蛋白，由可溶性 T 细胞受体与抗 CD3 免疫效应功能融合而成。KIMMTRAK 专门针对 gp100，这是一种在黑色素细胞和黑色素瘤中表达的谱系抗原。这是使用 Immunocore 的 ImmTAC 技术平台开发的第一个分子，旨在重定向和激活 T 细胞以识别和杀死肿瘤细胞。该药物于 2022 年 1 月获得美国 FDA 批准，并于 2022 年 4 月获得欧洲批准。截至 2025 年 11 月，已在 39个国家/地区推出，并在全球 28个国家上市，用于治疗 HLA-A*02:01 阳性且不可切除或转移性葡萄膜黑色素瘤 (mUM) 患者。KIMMTRAK 在其上市的大多数市场中继续成为治疗标准。
公司认为，在扩大 KIMMTRAK 的患者覆盖范围方面，有三个关键的增长领域，包括继续在全球范围内扩大 mUM 的覆盖范围、潜在地扩展到 2L+ 晚期皮肤黑色素瘤 (CM) 以及潜在地扩展到辅助性葡萄膜黑色素瘤。后者的阶段性进展：欧洲癌症研究与治疗组织 (EORTC) 继续扩大眼部黑色素瘤 3 期辅助治疗试验 (ATOM) 的试验点范围；公司估计，美国和欧洲 HLA-A*02:01 阳性、高危辅助性葡萄膜黑色素瘤患者群体可能多达 1200 人。
13 Harrow
Harrow 11 月 10 日报告称，2025 年第三季度的收入为 7160 万美元，比 2024 年第三季度的 4930 万美元增长了 45%。
3.1 报告期进展亮点
Vevye：2025 年第三季度的收入为 2260 万美元，高于 2024 年第三季度的 520 万美元，占公司收入的 32%。（用于治疗干眼症的药物，2023年5月FDA批准，一天使用2次。2024 年 1 月推出了 Vevye，一种治疗干眼症的无水环孢菌素制剂。）
Iheezo：2025 年第三季度的收入为 2190 万美元，高于 2024 年第三季度的 1290 万美元，占总收入的 31%。（用于视网膜手术的局部麻醉凝胶，2022年9月FDA批准，Iheezo 起效迅速（约 1 至 1.5 分钟），麻醉效果可持续约 20 分钟。）
3.2 全年销售指引
Harrow公司将2025年营收预期从8月份的2.8亿美元以上下调至2.7亿美元至2.8亿美元，主要原因是Triesence产品以及公司罕见病和特药产品组合的业绩表现不佳。Harrow公司于2023年获得Triesence在美国的销售权，并于2024年10月在美国重新推出该产品。这种不含防腐剂的合成药物已获美国批准，用于玻璃体切除术中的可视化以及治疗对局部皮质类固醇无反应的眼部炎症。Harrow首席执行官表示，基于多项积极趋势，他仍然看好Triesence的前景。Triesence 2025年第三季度的销量环比增长67%。
14 Sight Sciences
Sight Sciences 于 11 月 6 日报告称，其 2025 年第三季度的收入为 1990 万美元，比 2024 年第三季度的 2020 万美元下降了 1%。
4.1 青光眼手术业务
青光眼手术业务收入为 1970 万美元，比 2024 年第三季度的 1860 万美元增长了 6%。该公司表示，这主要是由于订购账户和平均售价的增加，但部分被 MAC 保险覆盖范围限制导致的多个 MIGS 手术与白内障手术联合实施的账户使用量下降所抵消。
4.2 干眼症业务
干眼症收入为 20 万美元，低于 2024 年第三季度的 150 万美元。称预期中的下降主要是由于 SmartLids 新销量减少，而这又是该公司专注于为 TearCare 手术争取医保报销的结果。
4.3 近期临床亮点
宣布将 TearCare系统纳入TFOS 干眼研讨会 (DEWS) III 全球干眼指南，该指南发表于《美国眼科杂志》，该报告讨论了基于临床数据的干眼症 (DED) 的诊断方法和治疗策略。
宣布在《欧洲眼科杂志》上发表系统文献综述和荟萃分析，结果表明 OMNI 可显著降低眼内压 (IOP) 和药物使用量，并随着时间的推移持续改善。
4.4 全年销售指引
Sight Sciences 将 2025 年全年收入预期上调至 7600 万美元至 7800 万美元，与 2024 年全年收入相比下降 2% 至 5%，而此前的收入预期为 7200 万美元至 7600 万美元。另外，由于公司的大部分产品在中国生产和组装，因此公司受到美国对中国征收关税的影响。公司预计，其青光眼手术业务板块的关税影响将导致该板块2025年全年的销售成本增加100万至150万美元。
15 ANI
ANI 11 月 7 日报告称，Iluvien 2025 年第三季度的收入为 1660 万美元。2024 年第四季度是 ANI 在 2024 年收购 Alimera Sciences 后拥有这些药物的第一个完整季度。ANI在2024年以 3.81 亿美元收购 Iluvien 和 Yutiq 的制造商 Alimera。
鉴于 Iluvien 已在初始适应证（糖尿病黄斑水肿）基础上，新增 Yutiq 的相关适应症标签 —— 即影响眼后段的慢性非感染性葡萄膜炎，ANI 已停止 Yutiq 的市场推广工作。
ANI 表示，Iluvien 净营收面临双重压力。一是联邦医疗保险（Medicare）患者用药可及性持续下降，这源于慈善组织等第三方共付费用援助项目缺乏资金支持；二是医生诊所仍在使用剩余的 Yutiq 库存产品。
2014 年，Iluvien 成为首个经玻璃体内注射且获得 FDA 批准用于治疗糖尿病性黄斑水肿的NBI（非生物可降解植入物）。这一规格为 0.19 mg 的缓释醋酸氟轻松玻璃体内植入物，借助 CONTINUOUS MICRODOSING™ 技术，旨在以平均每天 0.2 µg 的速率释放氟轻松，且这一释放过程可持续长达 36 个月之久。通过这样的缓释方式，其能够有效减少疾病的复发风险，助力患者在减少注射次数的前提下，更长时间地维持良好视力。
2018 年，Yutiq 同样是一种与氟轻松密切相关的NBI 获得了 FDA 的批准，用于慢性非感染性葡萄膜炎的治疗。该植入物经注射进入玻璃体腔内后，将以每天 0.25 µg 的速率释放 0.18 mg氟轻松，且整个释放时长可达 36 个月。特别指出的是，Yutiq由欧康维视（优施莹）引进并于2022年6月在国内上市。
ANI公布了其2025年各产品营收预期。该公司对Iluvien和Yutiq两款产品的2025年营收预期为7300万美元至7700万美元，低于8月份预测的8700万美元至9300万美元。
ANI公司还销售纯化的Cortrophin凝胶，其八种适应症包括眼科用途。公司暂未按细分领域披露该凝胶的销售数据。
16 Iridex
Iridex 于 11 月 11 日公布，其 2025 年第三季度的收入为 1250 万美元，比 2024 年第三季度的 1160 万美元增长了 8%。
青光眼产品：1）收入：用于进行经巩膜睫状体光凝术的 Cyclo G6 产品系列的收入为 350 万美元，比 2024 年第三季度的 310 万美元增长了 13%。2）销量：Iridex 在 2025 年第三季度销售了 30 台 Cyclo G6 青光眼激光系统，而 2024 年第三季度销售了 26 台；销售了14,900 个 Cyclo G6 探头，而 2024 年第三季度的销量为 13,600 个。
视网膜产品：视网膜产品收入为 670 万美元，比 2024 年第三季度的 650 万美元增长 4%。
更多财报，可点击下方图片：
声明：本文仅供医疗卫生专业人士学术交流，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息用于资讯以外的目的，本平台及作者不承担相关责任。
协会十周年祝贺视频
中国社会办医之歌
扫码访问网站
扫码关注公众号
扫码访问视频号
联 系 方 式
电话：18903076658
地址：广州市越秀区先烈中路云鹤北街8号海德公馆C栋6楼
转发是支持，阅读是肯定！感谢您的一路陪伴！
点赞
分享
推荐
2025-11-13
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter of its evolution today during an investor day event at the New York Stock Exchange.
Leading Through Reinvention
Over the past few years, Bausch + Lomb has undergone a complete transformation by redefining how it operates. The company has sharpened its focus through simplification, rebuilt its culture around accountability and innovation and embraced AI and other new technologies to succeed now and well into the future.
“Bausch + Lomb today is a fundamentally different company than it was just a few years ago,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “We’ve reignited a sense of ownership and ambition across the organization to better serve patients, customers and consumers and deliver sustainable, profitable growth.”
Three-Year Plan for Profitable Growth1
During the event, Bausch + Lomb leadership will unveil plans to achieve above-market revenue growth and meaningful margin expansion. The company’s target of 5 – 7% constant currency revenue CAGR2 through 2028 is expected to be driven by holistic growth in its base business and recent product launches across the spectrum of eye health needs. The company’s target of approximately 23% adjusted EBITDA (ex. Acq. IPR&D) margin2 in 2028 is expected to be fueled by continuous improvements to how it sources, makes and sells products, and an ongoing examination of opportunities to streamline internal processes. Bausch + Lomb will also announce additional financial targets of double-digit adjusted annual earnings per share growth (ex. Acq. IPR&D)2 from 2026 – 2028, approximately 50% adjusted cash flow from operations to adjusted EBITDA (ex. Acq. IPR&D) conversion2 in 2028 and net leverage2 of approximately 3.5x by the end of 2028.
The company will also reaffirm its 2025 guidance.
“Our roadmap to above-market growth and meaningful margin expansion is clear,” said Sam Eldessouky, executive vice president and chief financial officer, Bausch + Lomb. “We’re driving P&L leverage and making smart investments in innovation and execution to ensure that every dollar contributes to long-term value creation for our shareholders.”
Loaded and Differentiated Pipeline
Most of the event will be dedicated to Bausch + Lomb’s rebuilt product pipeline, with R&D and commercial leaders highlighting potential game-changing innovations at varying clinical stages in each business unit. Total projected peak sales of pipeline products, with anticipated peaks staggered based on launch dates, is approximately $7 billion.
“We’re pushing the boundaries of ocular science to transform how eye diseases – from common to complex – are understood, treated and ultimately prevented,” said Yehia Hashad, MD, executive vice president, R&D and chief medical officer, Bausch + Lomb. “We’ve been bringing new products to market at a record pace, and our innovation engine is built to sustain growth well into the next decade.”
Pipeline products by business that will be highlighted:
Consumer
New PreserVision ® formulation – AREDS3 – would support vision health in people with age-related macular degeneration (AMD) through the addition of a proprietary vitamin B complex ( anticipated launch: 1H 2026 )
New formulation of LUMIFY ® – the #1 eye doctor recommended redness reliever – combining brimonidine and hyaluronic acid would make for a more luxurious feeling drop with a fast onset of action ( anticipated launch: 1H 2027 )
Preservative-free lipid-based formulation of Blink ® Triple Care ( anticipated launch: 1H 2026 ) and new bottle technology under development would introduce additional science-backed OTC options for dry eye sufferers
Pharmaceuticals
Potential first-in-class dual-action eye drop combining the active ingredients of MIEBO ® and XIIDRA ® is expected to address both the evaporative and inflammatory causes of dry eye ( anticipated launch: ~2029 )
First neurosensory-targeted therapy for ocular surface pain – the #1 reason for visits to eye care professionals – would address a critical unmet need ( anticipated launch: ~2030 )
Glaucoma medication under development would be the first to treat vision loss in addition to lowering intraocular pressure ( anticipated launch: ~2031 )
Early-stage research collaborations designed to address unmet patient needs in intermediate AMD and geographic atrophy ( anticipated launch dates: 2030+ )
Surgical
enVista Beyond™ intraocular lens using pure refractive optics – no diffractive rings – expected to provide a continuous extended depth of focus and reduce dysphotopsias ( anticipated launch: 2027 )
ELIOS™ – already approved in Europe and backed by extensive clinical data – brings a truly implant-free minimally invasive glaucoma surgery approach, using excimer laser precision to create outflow channels safely and effectively ( anticipated U.S. launch: 2H 2026 )
SeeNova™, a new phaco and vitreoretinal platform, to offer enhanced fluidics and multi-function handpieces to make surgery more efficient ( anticipated launch: 2028 )
SeeLyra™, a next generation femtosecond laser, to feature live optical coherence tomography guidance and soft docking for accuracy and patient comfort ( anticipated launch: 2H 2026 )
Contact Lens
There has not been a new contact lens material breakthrough in the industry for more than 25 years; that would change with the planned introduction of a bioactive hyaluronic acid hydrogel lens, creating an entirely new category ( anticipated launch: 2028 )
Cost-competitive daily disposable silicon hydrogel lens would provide eye care professionals with a new option for price-conscious patients ( anticipated launch: 2029 )
Premium silicon hydrogel offering would introduce a new level of comfort in the frequent replacement lens category ( anticipated launch: 2029 )
Silicon hydrogel lens designed to slow the progression of myopia in children and young adolescents would address a growing need that’s becoming more and more urgent ( anticipated launch: 2029 )
The investor day presentation, which details the three-year financial targets and delves into the science behind each pipeline product, and webcast registration details are available on the Investor Relations section of the Bausch + Lomb website.
###
About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.
Forward-looking Statements
This news release contains forward-looking information and statements within the meaning of applicable securities laws (collectively, “forward-looking statements”), which may generally be identified by the use of the words “anticipates,” “expects,” “predicts,” “projects,” “goals,” “intends,” “plans,” “should,” “could,” “would,” “may,” “might,” “will,” “strive,” “believes,” “estimates,” “potential,” “target,” “commit,” “forecast,” “outlook,” “guidance,” “tracking” or “continue” and positive and negative variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements, including the Company’s 2025 full-year guidance, its three-year financial targets, anticipated launch dates for pipeline products and projected peak sales, are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs, and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission (“SEC”) and the Canadian Securities Administrators (the “CSA”), including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (which was filed with the SEC and CSA on February 19, 2025) and its most recent quarterly filings, which factors are incorporated herein by reference. They also include risks relating to the development of pipeline products, including the risk that studies may not produce successful results or demonstrate safety and efficacy in humans, risks that pre-clinical and clinical trials may be delayed (which, in turn, may delay the launch of these products) and risks that the regulatory approval of products may be lengthy, costly and, ultimately, not successful. They also include risks relating to the launch and commercialization of products, including risks relating to the costs, required resources and unpredictability of commercial launches, risks that products may not achieve the anticipated levels of market acceptance, which can result from a number of factors, many of which are outside of the Company’s control, risks that products may experience negative publicity or reputational harm, competitive risks, such as competitors beating the Company to market or developing new or better technologies and risks that the Company may face supply interruptions with finished products or components thereof, which, in turn, may impact the Company’s ability to successfully launch or commercialize products. They also include risks and uncertainties respecting the proposed plan to separate the Company into an independent, publicly traded company, separate from the remainder of Bausch Health Companies Inc. (“BHC”) (the “separation”), which include, but are not limited to, the expected benefits and costs of the separation, the expected timing of completion of the separation and its manner and terms (including that it may include the transfer of all or a portion of BHC’s remaining direct or indirect equity interest in Bausch + Lomb to its shareholders (the “distribution”)), the expectation that, if the separation is to be effected through a distribution, then it will be completed following the achievement of targeted debt leverage ratios, subject to market conditions and receipt of applicable shareholder and other necessary approvals and other factors (including those described in BHC’s public statements), the ability to complete the distribution considering the various conditions to the completion of the distribution (some of which are outside the Company’s and BHC’s control, including conditions related to regulatory matters and receipt of applicable shareholder and other approvals), the impact of any potential sales or dispositions of the Company’s common shares by BHC (including in connection with a foreclosure on the Bausch + Lomb common shares owned by BHC that are or maybe pledged as collateral for certain of BHC’s debt), that market or other conditions are no longer favorable to completing the transaction, that applicable shareholder, stock exchange, regulatory or other approval is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the separation, diversion of management time on separation-related issues, retention of existing management team members, the reaction of customers and other parties to the separation, the structure of the distribution, the qualification of the distribution as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue Service will be sought or obtained), the ability of the Company and BHC to satisfy the conditions required to maintain the tax-free status of the distribution (some of which are beyond their control), other potential tax or other liabilities that may arise as a result of the distribution, the potential dis-synergy costs resulting from the separation, the impact of the separation on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments and legal and regulatory rules affecting the Company’s business. In particular, the Company can offer no assurance that the separation will occur at all, or that any such transaction will occur on the terms and timelines or in the manner anticipated by the Company and BHC. They also include risks and uncertainties relating to acquisitions and other business development transactions the Company has completed or may, in the future, pursue and complete, including risks that pending transactions may not close, risks that the Company may not realize the expected benefits of those transactions on a timely basis or at all and, where applicable, risks relating to increased levels of debt as a result of debt incurred to finance such transactions, including in regards to compliance with the Company’s debt covenants. They also include the expected impact of the tariffs imposed by the U.S. and counter-tariffs or other retaliatory measures imposed on the U.S. by other countries and disruptions to global supply chains and other potential results as a result of these developments and the Company’s ability to successfully manage the expected impact of such tariffs and counter-tariffs and other measures, including the success of planned actions and levers to manage these matters. Finally, they also include, but are not limited to, risks and uncertainties caused by or relating to a potential recession and other adverse economic conditions (such as heightened inflation and interest rates, fluctuations in exchange rates, imposition of and adverse changes to tariffs, duties and other trade protection measures and slower growth), which could adversely impact the Company’s revenues, expenses and resulting margins. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including the assumption that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. In addition, management has also made certain assumptions regarding 2025 full-year guidance with respect to expectations regarding base performance growth, business performance, currency impact, impacts of inflation, the Company’s ability to offset the impact of tariffs in 2025 (based on the current tariff policy and the actions the Company is taking to manage these measures), adjusted gross margin (non-GAAP), adjusted SG&A expense (non-GAAP) and the Company's ability to continue to manage such expense in the manner anticipated, interest expense (which will vary based on, among other things, interest rates and the Company’s indebtedness), adjusted tax rate, and full year capex and the anticipated timing and extent of the Company's R&D expense. In addition, management has also made certain assumptions regarding its three year financial targets, including with respect to expectations regarding constant currency CAGRs for segments and businesses over the period, anticipated adjusted R&D expense, anticipated CapEx over the period, expectations regarding adjusted tax rate and anticipated share count.
Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
Non-GAAP Information
To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures and ratios. Management uses these non-GAAP measures and ratios as key metrics in the evaluation of the Company’s performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The Company believes these non-GAAP measures and ratios are useful to investors in their assessment of the Company’s operating performance and the valuation of the Company. In addition, these non-GAAP measures and ratios address questions the Company routinely receives from analysts and investors, and in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors.
These measures and ratios do not have any standardized meaning under GAAP and other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way the Company calculates such measures and ratios. Accordingly, the Company’s non-GAAP financial measures and ratios may not be comparable to similar non-GAAP measures and ratios of other companies. The Company cautions investors not to place undue reliance on such non-GAAP measures and ratios, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.
For outlook purposes, the Company does not provide reconciliations of projected Constant Currency Revenue Growth to projected GAAP Revenue Growth, projected Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) to projected GAAP net income (loss), projected Adjusted EBITDA Margin excluding Acquired IPR&D (non-GAAP) to projected GAAP net income (loss) margin, projected Adjusted Cash Flow from Operations to projected Cash flow from operations/Cash used in operations (loss) attributable to Bausch + Lomb Corporation, the components of projected net leverage to their GAAP equivalents (project net debt to debt and projected Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) to projected GAAP net income (loss)), or projected Adjusted EPS Attributable to Bausch + Lomb (excl. Acq. IPR&D) to projected Diluted income per share attributable to Bausch + Lomb Corporation (“GAAP EPS”) in each case, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. These amounts may be material and, therefore, could result in the projected GAAP measure or ratio being materially different or less than the projected non-GAAP measure or ratio. These statements represent forward-looking information and may represent a financial outlook, and actual results may vary. Please see the risks and assumptions referred to in the Forward-looking Statements section of this news release.
Specific Non-GAAP Measures
EBITDA, Adjusted EBITDA and Adjusted EBITDA excluding Acquired IPR&D
EBITDA (non-GAAP) is Net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable U.S. GAAP financial measure) adjusted for interest, income taxes, depreciation and amortization. Adjusted EBITDA (non-GAAP) is EBITDA (non-GAAP) further adjusted for the items described below. Management believes that Adjusted EBITDA (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that Adjusted EBITDA (non-GAAP) focuses management on the Company’s underlying operational results and business performance. As a result, the Company uses Adjusted EBITDA (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes Adjusted EBITDA (non-GAAP) is a useful measure to evaluate current performance. Adjusted EBITDA (non-GAAP) is intended to show unleveraged, pre-tax operating results and therefore reflects the Company’s financial performance based on operational factors. In addition, cash bonuses for the Company’s executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets. Adjusted EBITDA margin (non-GAAP) is Adjusted EBITDA (non-GAAP) divided by Revenues.
Adjusted EBITDA (non-GAAP) is Net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable U.S. GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization and further adjusted for the following items:
Asset impairments: The Company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The Company believes that the adjustments of these items correlate with the sustainability of the Company’s operating performance. Although the Company excludes impairments of intangible assets from measuring the performance of the Company and its business, the Company believes that it is important for investors to understand that intangible assets contribute to revenue generation.
Restructuring, integration and transformation costs: The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. With regard to infrastructure and operational improvements which the Company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. Additionally, with the completion of the Bausch + Lomb IPO, as the Company prepares for post-separation operations, the Company is launching certain transformation initiatives that will result in certain changes to and investment in its organizational structure and operations. These transformation initiatives arise outside of the ordinary course of continuing operations and, as is the case with the Company’s restructuring efforts, costs associated with these transformation initiatives are expected to fluctuate between periods in amount, size and timing. These out-of-the-ordinary-course charges include third-party advisory costs, as well as certain compensation-related costs. Investors should understand that the outcome of these transformation initiatives may result in future restructuring actions and certain of these charges could recur. The Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company’s operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.
Acquisition-related costs and adjustments excluding amortization of intangible assets: The Company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are significantly impacted by the timing and size of its acquisitions. In addition, the Company excludes the impact of acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments are not consistent and are significantly impacted by the timing and size of the Company’s acquisitions, as well as the nature of the agreed-upon consideration.
Share-based compensation: The Company excludes costs relating to share-based compensation. The Company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted.
Separation costs and separation-related costs: The Company has excluded certain costs incurred in connection with activities taken to: (i) separate the Bausch + Lomb business from the remainder of BHC and (ii) register the Bausch + Lomb business as an independent publicly traded entity. Separation costs are incremental costs directly related to effectuating the separation of the Bausch + Lomb business from the remainder of BHC and include, but are not limited to, legal, audit and advisory fees, talent acquisition costs and costs associated with establishing a new Board of Directors and Audit Committee. Separation-related costs are incremental costs indirectly related to the separation of the Bausch + Lomb business from the remainder of BHC and include, but are not limited to, IT infrastructure and software licensing costs, rebranding costs and costs associated with facility relocation and/or modification. As these costs arise from events outside of the ordinary course of continuing operations, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company’s operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.
Gain (Loss) on extinguishment of debt: The Company has excluded loss on extinguishment of debt as this represents a loss from refinancing its existing debt and is not a reflection of its operations for the period. Further, the amount and frequency of such amounts are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market that are not in management’s control. Bausch + Lomb did not have any material losses on extinguishment of debt prior to the second quarter of 2025.
Other Non-GAAP adjustments: The Company also excludes certain other amounts, including IT infrastructure investment, litigation and other matters, gain/(loss) on sales of assets and certain other amounts that are the result of other, non-comparable events to measure operating performance if and when present in the periods presented. These events arise outside of the ordinary course of continuing operations. Given the unique nature of the matters relating to these costs, the Company believes these items are not routine operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the Company believes the costs associated with legal settlements and judgments are not routine operating expenses. The Company excluded these costs as this event is outside of the ordinary course of continuing operations and infrequent in nature. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in the industry often face litigation.
Adjusted EBITDA excluding Acquired In-Process Research and Development (IPR&D) (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude Acquired IPR&D. Adjusted EBITDA Margin excluding Acquired In-Process Research and Development (IPR&D) is Adjusted EBITDA (non-GAAP) further adjusted to exclude Acquired IPR&D divided by Revenues. The IPR&D expenditures represent costs directly resulting from business development transactions and not through the normal course of business. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors in assessing the Company’s performance. However, investors should understand that the Company may enter into additional business development transactions in the future and, as a result, such Acquired IPR&D may recur in the future.
Constant Currency
Constant currency change or constant currency growth is calculated by adjusting or further adjusting a measure or ratio by changes in or impact of foreign currency exchange rates. Constant currency impact is determined by comparing 2025 amounts adjusted to exclude currency impact, calculated using 2024 monthly average exchange rates, to the actual 2024 reported amounts. Constant currency revenue is GAAP revenue (its most directly comparable GAAP financial measure) adjusted for changes in foreign currency exchange rates. The Company uses Constant Currency Revenues (non-GAAP) and Constant Currency Revenue Growth (non-GAAP) to assess performance of its reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations. The Company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison. Although changes in foreign currency exchange rates are part of the business, they are not within management’s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the underlying business performance.
Adjusted Cash Flow from Operations/Adjusted Cash Flow from Operations to Adj. EBITDA (excl. acq. IPR&D) conversion
Adjusted cash flow from operations (non-GAAP) is Cash flow from operations/Cash used in operations (loss) attributable to Bausch + Lomb Corporation (its most directly comparable GAAP financial measure) adjusted for: (i) payments of legacy legal settlements, net of insurance proceeds, if any (ii) payments for separation costs, IPO costs, separation-related costs, and IPO-related costs (iii) payments for business transformation costs and (iv) payments for financing fees related to the modification of debt, if any. Management believes that Adjusted cash flow from operations (non-GAAP), along with the GAAP and non-GAAP measures used by management, most appropriately reflect how the Company measures the business internally. The Company uses Adjusted cash flow from operations (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes Adjusted cash flow from operations (non-GAAP) is a useful measure to evaluate current performance amounts. As these payments arise from events outside of the ordinary course of continuing operations as discussed above, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company’s cash from operations, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors. Adjusted cash flow from operations to Adj. EBITDA (excl. acq. IPR&D) conversion is Adjusted cash flow from operations divided by Adjusted EBITDA (excluding Acquired IPR&D).
Net Leverage
Net Leverage is the ratio of net debt (which is calculated as total debt (its GAAP equivalent) less cash and cash equivalents) over Adjusted EBITDA (excluding Acquired IPR&D). Management believes that net leverage is an important measure of the Company’s overall liquidity position and an indicator of its ability to meet financial obligations.
Adjusted EPS (non-GAAP) and Adjusted EPS excluding Acquired IPR&D (non-GAAP)
Adjusted earnings per share or Adjusted EPS (non-GAAP) is calculated as Diluted income per share attributable to Bausch + Lomb Corporation (“GAAP EPS”) (its most directly comparable GAAP financial measure), adjusted for the per diluted share impact of each adjustment made to reconcile Net income (loss) attributable to Bausch + Lomb Corporation to Adjusted net income (non-GAAP) as discussed above. Adjusted EPS excluding Acquired IPR&D (non-GAAP) is Adjusted EPS (non-GAAP) further adjusted for the per diluted share impact of Acquired IPR&D. Like Adjusted net income (non-GAAP), Adjusted EPS (non-GAAP) and Adjusted EPS excluding Acquired IPR&D (non-GAAP) excludes the impact of certain items that may obscure trends in the Company’s underlying performance on a per share basis. By disclosing these non-GAAP measures, it is management’s intention to provide investors with a meaningful, supplemental comparison of the Company’s results and trends for the periods presented on a diluted share basis. Accordingly, the Company believes that Adjusted EPS (non-GAAP) and Adjusted EPS excluding Acquired IPR&D (non-GAAP) are useful to investors in their assessment of the Company’s operating performance, the valuation of the Company and an investor’s return on investment. It is also noted that, for the periods presented, the Company’s GAAP EPS was significantly lower than its Adjusted EPS (non-GAAP) and Adjusted EPS excluding Acquired IPR&D (non-GAAP).
© 2025 Bausch + Lomb.
1 The financial targets and guidance in this news release are only effective as of the date given, November 13, 2025, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed financial targets or guidance. Distribution or reference of this news release following November 13, 2025, does not constitute the Company re-affirming these financial targets and guidance. See the “Forward-looking Statements” section for further information.
2 This is a non-GAAP measure or ratio. For further information on non-GAAP measures and ratios, please refer to the “Non-GAAP Information” section of this news release.
100 项与 酒石酸溴莫尼定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼睛发红 | 美国 | 2017-12-22 | |
| 玫瑰痤疮 | 美国 | 2013-08-23 | |
| 青光眼 | 日本 | 2012-01-18 | |
| 低眼压 | 美国 | 2005-08-19 | |
| 开角型青光眼 | 美国 | 1996-09-06 | |
| 高眼压症 | 美国 | 1996-09-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 季节性过敏性结膜炎 | 临床3期 | 美国 | 2022-11-18 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2022-10-12 | |
| 先天性毛细血管畸形1 | 临床3期 | 加拿大 | - | 2016-06-01 |
| 红斑 | 临床3期 | 美国 | 2014-07-01 | |
| 充血 | 临床3期 | 美国 | 2013-11-07 | |
| 周围神经系统疾病 | 临床2期 | 法国 | 2025-09-01 | |
| 皮疹 | 临床2期 | 法国 | 2025-01-20 | |
| 毛囊炎 | 临床2期 | 法国 | 2025-01-20 | |
| 视网膜脱离 | 临床2期 | 美国 | 2009-11-01 | |
| 视网膜脱离 | 临床2期 | 印度 | 2009-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 229 | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution) | 襯鹹積簾艱鏇窪襯醖齋(糧積鏇淵衊齋淵憲醖衊) = 壓鬱壓顧壓淵鏇鹹築繭 蓋遞壓繭積鏇觸夢壓齋 (衊製顧餘鹽積鑰觸齋繭, 0.6031) 更多 | - | 2025-07-01 | ||
(Ketotifen Fumarate Ophthalmic Solution 0.035%) | 襯鹹積簾艱鏇窪襯醖齋(糧積鏇淵衊齋淵憲醖衊) = 繭鬱築鑰鹽範窪願鹽築 蓋遞壓繭積鏇觸夢壓齋 (衊製顧餘鹽積鑰觸齋繭, 0.3136) 更多 | ||||||
临床3期 | 188 | (Combination) | 蓋蓋積範選衊選艱觸簾(範獵衊獵獵鬱網鏇構範) = 製齋餘醖蓋繭鑰選鹹鹹 鹽夢顧築襯鹽選積窪觸 (衊糧築鏇繭鏇觸窪壓顧, 0.1464) 更多 | - | 2025-02-14 | ||
(Ketotifen Fumarate) | 蓋蓋積範選衊選艱觸簾(範獵衊獵獵鬱網鏇構範) = 膚範糧蓋膚網網鬱餘鬱 鹽夢顧築襯鹽選積窪觸 (衊糧築鏇繭鏇觸窪壓顧, 0.1487) 更多 | ||||||
临床3期 | 380 | (Brimonidine Tartrate Preservation-free) | 鬱構艱選觸鏇糧憲廠築(遞簾選鏇積醖範膚衊醖) = 餘遞築願糧膚築衊網構 衊構膚遞餘憲選餘構醖 (壓構襯衊壓鬱壓願艱選, 0.039) 更多 | - | 2024-08-26 | ||
鬱構艱選觸鏇糧憲廠築(遞簾選鏇積醖範膚衊醖) = 蓋網夢築願選獵壓願網 衊構膚遞餘憲選餘構醖 (壓構襯衊壓鬱壓願艱選, 0.041) 更多 | |||||||
临床2期 | 84 | Corticosteroid+Brimonidine (Brimonidine and Corticosteroid Combination Therapy) | 淵鹽繭膚範艱構壓積鹽(壓壓鏇衊醖網醖範積艱) = 築遞夢窪齋衊選網鏇簾 襯糧積壓獵蓋齋範顧艱 (鹽獵積積獵憲窪鏇構繭, 淵壓積齋餘蓋餘壓鬱膚 ~ 夢繭築簾構遞衊襯鹹餘) 更多 | - | 2022-07-06 | ||
(Brimonidine Monotherapy) | 淵鹽繭膚範艱構壓積鹽(壓壓鏇衊醖網醖範積艱) = 遞鹹衊憲齋鹽觸醖壓遞 襯糧積壓獵蓋齋範顧艱 (鹽獵積積獵憲窪鏇構繭, 簾衊夢鏇鹽顧糧廠觸窪 ~ 淵窪窪獵齋襯膚鑰膚繭) 更多 | ||||||
临床3期 | 252 | 築簾顧憲鬱繭憲鑰範窪(醖觸鹽壓鹽餘鑰窪範鏇) = 獵艱淵獵範觸壓鹽夢蓋 觸選遞築範壓糧窪醖顧 (窪遞醖鏇範餘範構鹽蓋, 13.6) 更多 | - | 2022-06-06 | |||
临床2期 | 13 | (Brimonidine Tartrate 0.2%) | 築築鹽製鏇鹹鬱顧願製(鹹遞憲顧憲鹽膚餘選醖) = 糧鏇觸範餘築夢範壓鏇 壓積遞構觸簾壓積鹹醖 (鏇構獵齋繭襯顧鑰鏇襯, 2.57) 更多 | - | 2022-04-20 | ||
(Control - Untreated) | 築築鹽製鏇鹹鬱顧願製(鹹遞憲顧憲鹽膚餘選醖) = 憲顧壓鏇築夢淵淵簾鑰 壓積遞構觸簾壓積鹹醖 (鏇構獵齋繭襯顧鑰鏇襯, 1.20) 更多 | ||||||
临床3期 | 682 | 夢蓋網繭餘築範繭鬱顧(獵顧廠構餘壓製網醖構) = 窪淵築願廠鬱範簾窪齋 齋簾膚窪膚醖簾膚窪選 (構顧獵顧壓願鬱廠築觸, 3.746) 更多 | - | 2022-02-15 | |||
(Brimonidine Tartrate Ophthalmic Solution) | 夢蓋網繭餘築範繭鬱顧(獵顧廠構餘壓製網醖構) = 選衊築鬱積廠淵網艱餘 齋簾膚窪膚醖簾膚窪選 (構顧獵顧壓願鬱廠築觸, 3.724) 更多 | ||||||
临床4期 | 43 | (Lumify Eye Drop) | 醖鑰繭選鏇鬱觸壓鏇築(衊壓餘鏇遞願夢壓鏇醖) = 鹽鹽製獵簾鬱蓋範願構 鑰製積構窪鏇網願築觸 (蓋糧構壓壓範蓋鏇願餘, 1.71) 更多 | - | 2021-06-14 | ||
Sterile balanced saline solution (Saline Solution Eye Drop) | 醖鑰繭選鏇鬱觸壓鏇築(衊壓餘鏇遞願夢壓鏇醖) = 顧廠網餘範繭顧齋蓋鏇 鑰製積構窪鏇網願築觸 (蓋糧構壓壓範蓋鏇願餘, 1.62) 更多 | ||||||
临床4期 | 35 | (Brimonidine) | 醖壓選構廠積餘顧網淵(鏇齋糧繭衊膚憲艱餘選) = 艱獵蓋鏇製積鏇衊餘積 餘顧製鏇壓獵窪鏇網鹹 (願積觸簾鹹鏇範衊觸壓, 6.10) 更多 | - | 2020-12-31 | ||
(Timolol) | 醖壓選構廠積餘顧網淵(鏇齋糧繭衊膚憲艱餘選) = 觸築繭觸獵襯餘鑰窪糧 餘顧製鏇壓獵窪鏇網鹹 (願積觸簾鹹鏇範衊觸壓, 6.47) 更多 | ||||||
临床3期 | 552 | (Test Product) | 遞夢膚餘選鹹膚糧夢鏇 = 鏇範襯艱網構壓鏇製觸 構鑰餘鏇製簾憲願鑰襯 (襯齋鬱構獵鏇夢淵鬱糧, 醖醖糧膚糧夢餘顧遞選 ~ 憲衊鏇築淵簾構顧製壓) 更多 | - | 2020-12-14 | ||
(Reference Product) | 遞夢膚餘選鹹膚糧夢鏇 = 餘積蓋築繭壓憲醖衊觸 構鑰餘鏇製簾憲願鑰襯 (襯齋鬱構獵鏇夢淵鬱糧, 壓選淵襯襯醖積築壓齋 ~ 膚艱襯蓋窪艱窪膚蓋構) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用